LIM
FLNA

Leavell Investment Management’s Filana Therapeutics FLNA Stock Holding History

Leavell Investment Management’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-11,200
Closed -$315K – 442
2022
Q2 		$315K Buy
+11,200
New +$283K 0.02% 364

Other funds holding FLNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Leavell Investment Management's FLNA Position: Q3 2022 in Review

Leavell Investment Management sold out of Filana Therapeutics (FLNA) in Q3 2022, closing a stake of 11,200 shares — an estimated $315K sold.

Leavell Investment Management first reported a position in FLNA in Q2 2022 and held it in 1 quarter. The position peaked at $315K in Q2 2022. 175 funds tracked by Wall St. Rank hold FLNA as of Q3 2022.

  • Leavell Investment Management reported no remaining Filana Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Leavell Investment Management sold 11,200 Filana Therapeutics shares in Q3 2022, an estimated $315K.
  • Leavell Investment Management first reported a position in Filana Therapeutics in Q2 2022 and held it in 1 quarter.
  • Leavell Investment Management's Filana Therapeutics position peaked at $315K in Q2 2022.
  • 175 funds tracked by Wall St. Rank held Filana Therapeutics as of Q3 2022.

Based on Leavell Investment Management's 13F filing for Q3 2022, filed 17 Oct 2022.